Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Heart failure, a condition where the heart struggles to pump blood efficiently to meet the body's needs, comes in various forms and one of them, heart failure with preserved ejection fraction ...

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

Heart failure normal ejection fraction (HFNEF) is growing at an alarming rate and has a complex pathophysiology. The mortality and morbidity of HFNEF is comparable to heart failure with reduced ...

Part 3: Heart Failure With Reduced Ejection Fraction: Diagnosis and Evaluation. Part 4: Case Study: Lightheadedness, Fatigue in Man With Hypertension. Up next: Medical Management ...

While heart failure overall is decreasing in age-specific incidence, the trends diverge by ejection fraction. For example, in a study from the Minnesota county near the Mayo Clinic, age- and sex ...